Transparency of vaccine purchase contracts

19.2.2021

Question for written answer  E-001016/2021
to the Commission
Rule 138
Cindy Franssen (PPE)

The European vaccine strategy[1] is designed to ensure sufficient supplies in the EU through advance purchase agreements with manufacturers. This has to date resulting in the signing of six contracts with Pfizer/BioNTech, CureVac, AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV and Moderna. Given the importance of transparency regarding these contracts in winning public confidence and commanding sufficient supplies, can the Commission provide the following information:

• 1.With only two of the contracts (with CureVac and AstraZeneca) available in redacted form, what has it done to make the remaining four contracts public?
• 2.Who inside the Commission has full access to the contents of the vaccine contracts concluded?
• 3.Which Member State representatives have full access to the contents of the vaccine contracts concluded?

• [1] EUR-Lex - 52020DC0245 - EN - EUR-Lex (europa.eu)